METHOXSALEN
Information current as at: 1 September 2026
Submission Details
- Brand name:
-
- Uvadex®
- Form and strength:
-
- Solution for blood fraction 20 microgram per mL, 10 mL
- Submission sponsor:
- HEALTH TECHNOLOGY ANALYSTS PTY LIMITED
- Condition/indication:
(therapeutic use) -
- Cutaneous T-cell lymphoma (CTCL) Chronic graft versus host disease (cGVHD)
- Listing requested:
- To request a change to the existing listings for methoxsalen for CTCL and cGVHD to allow consultant or specialist dermatologists to prescribe treatment.
- Funding program:
- PBS Section 100 (Highly Specialised Drugs Program)
- Request authority level:
- Authority Required (STREAMLINED)
- PBAC Submission type:
- Change to existing listing (Category 3)
- Comment:
- --
- Other PBAC consideration:
- --
Progress Details
-
Submission received for: - July 2026 PBAC meeting
-
Opportunity for consumer comment: - Open 25/03/2026 and close 20/05/2026 (see PBS Website)
-
PBAC meeting: - Held on 08/07/2026
-
PBAC outcome published: - Recommended (see PBAC Outcomes)
-
Notice of intent submitted:
- Awaiting lodgement from pharmaceutical company
-
5Lodgement of required documentation:
-
6Agreement to listing arrangements:
- Has not yet commenced
-
7Government processes:
- Has not yet commenced
-
8Medicine listed on the PBS:
- Has not yet occurred
PBAC Outcome
The PBAC recommended extending the current listing for methoxsalen (Uvadex®) for the treatment of cutaneous T-cell lymphoma (CTCL) and chronic graft-versus-host disease (cGVHD) to allow treatment by a dermatologist, or treatment by a medical practitioner working under the supervision of a dermatologist, as part of treatment with integrated, closed system extracorporeal photopheresis (ECP). The PBAC considered the eligible population for methoxsalen will likely be unchanged by the amendment of the treatment criteria and considered that there would be nil financial impact to the PBS.